BeiGene Ends Anti-TIGIT Development In Lung Cancer

BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.

BeiGene
BeiGene is moving on from the anti-TIGIT mechanism in immuno-oncology

The biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell lung cancer (NSCLC) after an independent data monitoring committee recommended termination of the study.

Key Takeaways
  • BeiGene has decided to terminate a Phase III study of anti-TIGIT agent ociperlimab in non-small cell lung cancer after a data monitoring board said it was not likely to improve overall survival.
  • Ociperlimab joins candidates such as Roche’s tiragolumab and Merck & Co.’s vibostolimab on the discard pile of TIGIT inhibitors

The Chinese and American cancer-focused biotech did not provide data from the discontinued AdvanTIG-302 study, but said the committee’s determination it was unlikely to demonstrate overall survival (OS) was based on a pre-planned futility analysis of the trial, which was testing ociperlimab combined with BeiGene’s anti-PD-1 drug Tevimbra (tislelizumab) against a control arm of Merck & Co

More from Strategy

More from Therapy Areas